Cargando…

The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study

INTRODUCTION: The dihydroorotate dehydrogenase (DHODH) inhibitors leflunomide and teriflunomide are immunomodulatory agents approved to treat rheumatoid arthritis (RA) and multiple sclerosis, respectively, and are actively being investigated as therapeutic agents for other immune-related diseases; h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muehler, Andreas, Kohlhof, Hella, Groeppel, Manfred, Vitt, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890621/ https://www.ncbi.nlm.nih.gov/pubmed/31621054 http://dx.doi.org/10.1007/s40268-019-00286-z

Ejemplares similares

Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects
por: Muehler, Andreas, et al.
Publicado: (2020)

Clinical relevance of intestinal barrier dysfunction in common gastrointestinal diseases
por: Muehler, Andreas, et al.
Publicado: (2020)

Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial
por: Vehreschild, Maria J. G. T., et al.
Publicado: (2022)

A double‐blind, randomized, placebo‐controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing‐remitting multiple sclerosis
por: Fox, Robert J., et al.
Publicado: (2022)

A pilot study of vidofludimus calcium for treatment of primary sclerosing cholangitis
por: Carey, Elizabeth J., et al.
Publicado: (2022)

Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD
por: Zhu, Yanlin, et al.
Publicado: (2020)

IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro
por: Hahn, Friedrich, et al.
Publicado: (2020)

Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Patterns of Anti-Inflammatory and Immunomodulating Drug Usage and Microvascular Endothelial Function in Rheumatoid Arthritis
por: Mangoni, Arduino A., et al.
Publicado: (2021)

Novel Dihydroorotate Dehydrogenase Inhibitors with Potent Interferon-Independent Antiviral Activity against Mammarenaviruses In Vitro
por: Kim, Yu-Jin, et al.
Publicado: (2020)

Interaction of Streptococcus pyogenes with extracellular matrix components resulting in immunomodulation and bacterial eradication
por: Colineau, Lucie, et al.
Publicado: (2020)

Vitamin D and immunomodulation in early rheumatoid arthritis: A randomized double-blind placebo-controlled study
por: Buondonno, Ilaria, et al.
Publicado: (2017)

Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis
por: Solomon, Daniel H, et al.
Publicado: (2023)

Immunomodulation of Autoimmune Arthritis by Herbal CAM
por: Venkatesha, Shivaprasad H., et al.
Publicado: (2011)

Immunomodulation, Bioavailability and Safety of Bacteriocins
por: Guryanova, Svetlana V.
Publicado: (2023)

Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data
por: Gharaibeh, Mahdi, et al.
Publicado: (2020)

Rheumatoid arthritis and the role of oral bacteria
por: Loyola-Rodriguez, Juan Pablo, et al.
Publicado: (2010)

Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy
por: Lu, Yun-Chi, et al.
Publicado: (2019)

Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program
por: Emery, Paul, et al.
Publicado: (2014)

An Analysis of the Neuropathic Pain Components in Rheumatoid Arthritis Patients
por: Ito, Satoshi, et al.
Publicado: (2017)

Characteristics of Appendicular Tissue Components in Patients with Rheumatoid Arthritis
por: Koo, Bon San, et al.
Publicado: (2020)

Adiponectin Is a Component of the Inflammatory Cascade in Rheumatoid Arthritis
por: Łączna, Małgorzata, et al.
Publicado: (2022)

Oral anticoagulant treatment in rheumatoid arthritis patients with atrial fibrillation results of an international audit()
por: Semb, Anne Grete, et al.
Publicado: (2022)

Apitoxin and Its Components against Cancer, Neurodegeneration and Rheumatoid Arthritis: Limitations and Possibilities
por: Aufschnaiter, Andreas, et al.
Publicado: (2020)

Efficacy and Safety of Qiwei Tongbi Oral Liquid in Patients with Stable Long-Standing Rheumatoid Arthritis
por: Lu, Wenjun, et al.
Publicado: (2021)

Safety and Efficacy of Tocilizumab for the Treatment of Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2012)

Safety of etanercept in elderly subjects with rheumatoid arthritis
por: Lurati, Alfredomaria, et al.
Publicado: (2010)

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2013)

Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis
por: Li, Jiangtao, et al.
Publicado: (2013)

Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study
por: Fleischmann, Roy, et al.
Publicado: (2022)

Oral contraceptives, breastfeeding and the risk of developing rheumatoid arthritis: results from the Swedish EIRA study
por: Orellana, Cecilia, et al.
Publicado: (2017)

Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)
por: Kameda, Hideto, et al.
Publicado: (2021)

Evaluation of Oral Health Status and Oral Care of Patients with Rheumatoid Arthritis
por: Radwan-Oczko, Małgorzata, et al.
Publicado: (2020)

Immunomodulation of dendritic cells by Lactobacillus reuteri surface components and metabolites
por: Engevik, Melinda A., et al.
Publicado: (2021)

Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population
por: Hall, Stephen, et al.
Publicado: (2018)

Immunomodulatory effect and safety of TNF-α RNAi mediated by oral yeast microcapsules in rheumatoid arthritis therapy
por: Hu, Nan, et al.
Publicado: (2022)

Differences in the Oral Microbiome in Patients With Early Rheumatoid Arthritis and Individuals at Risk of Rheumatoid Arthritis Compared to Healthy Individuals
por: Kroese, Johanna M., et al.
Publicado: (2021)

Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY
por: Strand, Vibeke, et al.
Publicado: (2020)

Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical program
por: Kakehasi, Adriana Maria, et al.
Publicado: (2023)

Predictors of frequent oral analgesic use in rheumatoid arthritis
por: Gupta, Esha das, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_do4b9pa8i544k58la96d5en64m